Archive for the ‘Xofigo’ Category

Xofigo prostate cancer drug reported to reduce pain

Wednesday, August 7th, 2013

prostatecancerdrugs

Xofigo, a newly approved treatment for advanced prostate cancer that has spread to the bones, is said to reduce patient pain levels.  The drug, which mimics calcium by binding to bone tissue at tumor sites, has been shown to extend patient survival rates by three months. The binding action of  Xofigo allows physicians to target the precise location of bone tumors caused by prostate cancer, and minimizes bone damage caused by tumors.  It is reported that Xofigo may allow patients to delay chemotherapy and the use of morphine for pain management.  A Xofigo treatment can be administered in a few as 15 minutes.

This prostate cancer news is brought to you by UroSciences– makers of the UroStop variable tension penile loop for sexual incontinence and the PDAD Peyronie’s disease assessment device.

 

 

New Mexico Cancer Center offering Xofigo for prostate cancer

Wednesday, August 7th, 2013

xofigo

The New Mexico Cancer Center has begun offering Xofigo to its prostate cancer patients.   Made by Bayer Healthcare, Xofigo, radium -223, has shown promise in recent studies for extending the survival rates of patients with advanced prostate cancer.  Xofigo works by mimicking calcium within the body and binding to areas of rapid bone growth caused by bone tumors, thus limiting the damage caused by the tumors.  Xofigo, once known as Alpharadin, received marketing approval from the FDA on May 15, 2013.

 

Check in with our UroSciences blog for the very latest news on prostate cancer, Peyronie’s disease, climacturia, and other urology topics.  Learn more about our PDAD device for assessing Peyronie’s disease, and the UroStop for preventing urine leakage during sex.

The UroStop variable tension penile loop for sexual incontinence.

The UroStop variable tension penile loop for sexual incontinence.